Sanofi poached Novaral and Gilead to target BMS MNC executives

Sanofi's new CEO, Novart's new president, Gilead's new chief commercial officer have announced that foreign media have revealed that AstraZeneta's chairman, CEO or will leave.1. Sanofi's newon June 7th, Sanofi's new CEO candidate finally surfaced. From September 1, 2019, Paul Hudson will take over from Olivier Brandicourt, who is retiring as chief executive of Sanofi., who previously served as Chief Executive Officer of Novarma Pharmaceuticals and a member of Novarce's Executive Committee, has accumulated 28 years of experience in the pharmaceutical industry. He has worked for GSK, Shilling ya, AstraZeneta, Novarma and other well-known multinational pharmaceutical companies, and has leadership and management experience in the U.S., Japan and Europe. In May 2016, Novarma's pharmaceutical business was restructured and split into two business units, Novarma Pharmaceuticals and Novarma Oncology, with former AstraZenecom US President and Executive Vice President of North America Paul Han as Novarma Pharmaceuticals Global CEO.management said Han Paul will help the company meet new strategic challenges, particularly in research and development and digital.joined Sanofi in April 2015 after serving as Bayer's chief executive. Sanofi was in trouble at the time, the diabetes business was under price pressure and a new batch of drugs was waiting to be developed. He joined as part of a restructuring and cost-cutting effort to gradually improve Sanofi's performance by focusing on five business units in General Medicine and Emerging Markets, Specialist Care, Diabetes and Cardiovascular, Vaccines, Animal Health, and strengthening the Kenzan Rare Diseases business.Sanofi's performance fell in 2018 and revealed it had cut its pay by 25 per cent. In this context, whether Han Paul, who will take office in September, can bring about a new shift in Sanofi's performance is also expected.
novart announces the new presidentAs Han Paul was confirmed as its new CEO, Novarma announced a new president, appointing Marie France Tschudin as Novarma's president and joining Novarma's executive board.Tschudin has worked for Janssen Pharmaceuticals, Shilling Ya and Xinji. In biopharmaceuticals, Tschudin started as a sales representative for Janssen-Cilag, a subsidiary of Johnson and Johnson, and worked at New Base for 10 years before joining Novarma. During her time at DJI, she led The New Base's blood business in Europe, the Middle East and Africa.January 2017, she joined Novaral as Head of Europe, managing a diverse team that generated more than $8 billion in sales. She is currently president of Advanced Accelerator Applications (AAA), a French oncology drug company that Novaral acquired in 2017.for the new president, she will next have a heavy burden on Novart's new listing and internal management., Novarca CEO Vas Narasimhan mentioned Novarce's plans to launch 25 drugs in the next few years, including 10 potentially heavy-duty drugs. And with Novartis's growing product line, such as CAR-T cell therapy Kymriah, known as the most expensive drug ever developed, a gene therapy for spinal muscular dystrophy, Zolgensma, multiple sclerosis drug Mayzent and other new therapies on the market, how quickly to expand the market for these new products is important. In addition, Novarce CEO Vanshwar's current strategic direction is to focus on new areas such as digital, big data and artificial intelligence, some of which Tschudin will do.3. Will AstraZenecom's Chairman and CEO leave?, AstraZeneta is looking for a successor to its chairman, according to Sky News.Leif Johansson has been chairman of the British pharmaceutical giant since 2012. Under the UK independent director system, independent directors are subject to conditional term limits, and the principle of "observance or interpretation" of the term of office of an independent director is subject to a statement of independence for a term of more than nine years, so long as the board of directors or the general meeting of shareholders considers the independent director to be independent. It comes seven years after Leif Johansson became AstraZeneta's chairman, and less than two years before a decision on re-election and the need for an independent statement.other British media reports, people familiar with the matter said AstraZeneta has not set a clear timetable for the replacement, but the company's nomination and governance committee is closely monitoring the matter. foreign media said AstraZeneta declined to respond to the reports. At the same time, Pascal Soriot, AstraZeneca's global CEO, faces a similar situation, joining AstraZeneca as global CEO at the 2012 time point. Leif Johansson and Pascal Soriot have helped AstraZeneta weather a series of drug patent expirations since his tenure, particularly the merger crisis. Pfizer had planned to buy AstraZeneca for 69.4 billion pounds ($730 billion) in 2014, which would have been the biggest acquisition in the pharmaceutical industry's history. And eventually AstraZeneta was able to weather the takeover crisis, which had to mention the efforts of chairman Leif Johansson and CEO Pascal Soriot. soriot even made a commitment to achieve $40 billion in results by 2023 to prevent acquisitions. AstraZeneta achieved $21 billion in sales in 2018, and while it is still a long way from its target, Soliot has publicly said it expects it to remain on target. Earlier, Leif Johansson referred to the RULES of the UK's independent director system in an interview with a Swedish media outlet. He added: "I am aware of the rule, but no decision has been made on whether to succeed me or Pascal." " investor believes that Leif Johansson will leave within 18 months and that his successor will be looking for a replacement for Soriot. is not the only pharmaceutical giant in the UK looking for a new chairman. GSK also officially announced in January that its chairman, Philip Hampton, had told the board that he was stepping down and that the board had begun looking for a successor. Pfizer is divesting its consumer health business, he said, "and I think this is the right time to step down, let the new chairman oversee the process over the next few years and lead GSK to a new phase". 4. Gilead will bring in the new Chief Commercial officer the end of May, Gilead also announced a new leadership team members. Johanna Mercier will serve as Chief Commercial Officer of Gilead Sciences from July 1. , Johanna Mercier led BMS' operations in the U.S., Germany, France and Japan. In August 2017, Johanna Mercier became head of commercial operations for BMS in the United States, and a year later was responsible for both commercial operations in Germany, France and Japan. is about to inject new forces like Johanna Mercier, executive changes and job transfers appear to be those that Gilead needs to address next. 9 December 2018, Gilead Sciences announced that Daniel O'Day will serve as Chairman and Chief Executive Officer of the Board of Directors as of March 1, 2019. After he took the helm, he quickly began to integrate his team, but it was clear that he would face operational pressure from personnel changes. Robin Washington, Gilead's longtime chief financial officer, has announced plans to retire in March, while Alessandro Riva, the company's executive vice president and head of the Oncology and Cell Therapy Center, left in March. (E drug manager)